| Lost password
627 users onlineYou are not loggend in.  Login
RT and alteplase
 1
 1
08/21/2015 19:07
dpjcrfsh 
08/21/2015 19:07
dpjcrfsh 
RT and alteplase

Sounds like alteplase is one of the most promising future treatments of DD. Since I'm considering RT, I'm curious if there is any possibility the RT would interfere with future treatment with alteplase. Any thoughts?

08/22/2015 07:00
wach 

Administrator

08/22/2015 07:00
wach 

Administrator

Re: RT and alteplase

Where did you get that from? To my knowledge there are no published results of a reasonably sized trial that would confirm this. Anecdotal reports from patients seem to indicate that it helps better for Ledderhose than for Dupuytren`s http://www.dupuytren-online.info/dupuytr...s_research.html.

Wolfgang

08/22/2015 11:11
dpjcrfsh 
08/22/2015 11:11
dpjcrfsh 
Re: RT and alteplase

From the patent application (http://www.dupuytren-online.info/Forum_E...&thema=2045) is the following except:

In the following examples the treatment of a number of patients suffering from Dupuytren's disease (palmar fascial fibromatosis) will be discussed. To date 100 patients suffering from Dupuytren's disease and 4 patients suffering from Ledderhose disease have been treated by the method of the invention using a recombinant tissue plasminogen activator. Specifically, the recombinant tissue plasminogen activator used is Alteplase as part of the commercially available formulation Actilyse™.

In general terms, at least 95% of the patient's suffering from Dupuytren's disease have reported satisfaction with the outcome after one or two rounds of treatment due to a greatly increased range of motion in the affected digits/regions. For those presenting with very pronounced cords or nodules then stripping out of the cord/nodule may be desirable for at least cosmetic reasons. In these cases the stripping procedure is also greatly simplified as a result of the treatment of the invention by comparison to surgery on a Dupuytren's patient who has not had the present treatment. This is as a result of the softening of the tissue.

The outcome of the present treatment was even better for patients suffering from Ledderhose disease in that all patients reported complete satisfaction with the return to function of the affected tissue.


I'm curious why there have been no reports on this forum from individuals involved in the study.

08/22/2015 15:57
spanishbuddha 

Administrator

08/22/2015 15:57
spanishbuddha 

Administrator

Re: RT and alteplase

There are lots of miracle cures out there, but until results from trials are published, reviewed and verified it becomes a bit ho hum. No harm in asking of course, and doing your own (literature) research and feeding back the outcome. If the inventor had been willing to present a paper at the recent international Dupuytren's conference, Wolfgang would have known.

08/23/2015 06:10
wach 

Administrator

08/23/2015 06:10
wach 

Administrator

Re: RT and alteplase

A patent is not a reliable source of information, it`s more of a claim. There seem to be no efforts to make this treatment gererally available, neither through publications nor through pharmaceutical companies. Dr. Chin was invited to present a paper on his alteplase treatment in Groningen but did not submit anything.

Wolfgang

spanishbuddha:
There are lots of miracle cures out there, but until results from trials are published, reviewed and verified it becomes a bit ho hum. No harm in asking of course, and doing your own (literature) research and feeding back the outcome. If the inventor had been willing to present a paper at the recent international Dupuytren's conference, Wolfgang would have known.


Edited 08/23/15 09:18

11/07/2016 22:44
Doblake 
11/07/2016 22:44
Doblake 
Re: RT and alteplase

Owen B. Can anyone give me Dr. Chin full name and where he practices. I am desperate to stop the pain in my feet from LD.

 1
 1
fibromatosis   Ledderhose   treatment   Specifically   spanishbuddha   plasminogen   patients   satisfaction   pharmaceutical   suffering   alteplase   dupuytren-online   international   disease   possibility   publications   commercially   Dupuytren   recombinant   &thema=2045